Obermatt
See Similar Stocks →

PolyPeptide

SWX:PPGN · CH1110760852
Life Sciences Tools & ServicesSmall

360

37
EV / EBIT13
Price / Owner Earnings82
Owner Earnings Yield1
Dividend Yield1
Price/Sales31
EV / Gross Profit11
Price/Book28
Return on Capital48
Cash Return on Capital21
Return on Equity48
EBIT Margin47
Gross Profitability16
Accruals21
Owner Earnings Margin28
Sales growth66
Profit growth34
Reinvestment12
Price momentum89
Debt load52
Refinancing62
Debt Payback1
Liquidity36
Analyst ratings20
Opinion Changes50
Price Target Upside19
Market mood25
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

PolyPeptide clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryGuernsey
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeSWX
Founded2021
Employees1,211
Websitepolypeptide.com
ISINCH1110760852
Last UpdateApr 2, 2026
Indices
SPI (Switzerland)
Themes
EndocrinologyPackaging ServicesOncologyManufacturing

Description

PolyPeptide Group AG operates as a leading pharmaceutical company specializing in the development and manufacturing of peptide-based therapeutics. The company excels with its full-service peptide-based drug solutions, covering research, development,…

Analysis

Middle-of-the-road

PolyPeptide Group AG is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is adequate. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
8
2023202420252026

All-time high

49

Jan 2025

All-time low

8

Jun 2026

Average rank

27

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
31
56
62
20
Price/Earnings
1
3
83
25
Price/Book
28
58
83
14
Dividend Yield
1
26
29
34
Value (overall)
6
32
46
21

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare PolyPeptide with its peers
SCHOTT Pharma AG & Co
GER:1SXP
62
CountryGermany
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Pentixapharm
GER:PTP
22
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeX-Small
Full Stock Analysis →
M&G Credit Income Investment Trust
LSE:MGCI
—
CountryUK
IndustryCapital Markets
SizeSmall
Full Stock Analysis →
Capital Limited
LSE:CAPD
100
CountryUK
IndustryMetals & Mining
SizeSmall
Full Stock Analysis →
XCHG
NMQ:XCH
53
CountryGermany
IndustryElectrical Equipment
SizeSmall
Full Stock Analysis →
RM
LSE:RM.
49
CountryUK
IndustrySoftware
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →